ASQ: IT can ameliorate health worker shortage

Health IT, especially EMRs, can help organizations and patients deal with the expected shortage of U.S. healthcare workers, according to a survey from the American Society for Quality (ASQ).

The healthcare worker shortage will result in more fragmented, uncoordinated care, longer waits and an increased possibility of medical errors, according to a poll of 475 ASQ-member U.S. healthcare quality professionals. Quality will be most affected by shortages of primary care physicians (cited by 44 percent of respondents), and shortages of nurses and nursing assistants (cited by 27 percent of respondents), stated ASQ, based in Milwaukee.

The U.S. Department of Health and Human Services predicts that healthcare staffing shortages will increase significantly after 2014, when approximately 32 million more people will be insured under the healthcare reform law, and as more baby boomers reach Medicare age.

Use of health IT systems; checklists in the ER and other departments; more care teams of doctors, nurses, physician assistants; and disease educators also can help, according to ASQ.

Respondents identified EMRs as the IT system that will provide the most value in reducing the impact of staff shortages. In addition, increased use of quality and process engineers should be the top priority for hospitals to reduce costs in light of shortages, respondents said.

Other methods identified by the ASQ poll include:
  • Implement mandatory process improvement training for healthcare;
  • Create financial incentives to deliver more efficient care;
  • Redesign hospital care spaces to be more efficient; and
  • Change malpractice laws.
 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.